Thoughts on Keynote 427 - Single Agent Pembrolizumab

Thoughts on Keynote 427 - Single Agent Pembrolizumab

User Photo
obr

2 years
222 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
David I. Quinn, MD, explains discusses Keynote 427 for Pembrolizumab, PD-1 Inhibitor and CTLA4 with Nivolumab & Ipilimumab presented at the 2018 Annual Meeting Annual Meeting.
Up Next Autoplay
>